Cardinal Health Inc CAH
We take great care to ensure that the data presented and summarized in this overview for CARDINAL HEALTH INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CAH
View all-
Vanguard Group Inc Valley Forge, PA30.6MShares$3.03 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY27.3MShares$2.71 Billion0.07% of portfolio
-
State Street Corp Boston, MA14.1MShares$1.4 Billion0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA5.57MShares$552 Million0.06% of portfolio
-
Morgan Stanley New York, NY4.37MShares$433 Million0.04% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4.14MShares$410 Million0.43% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.73MShares$369 Million1.08% of portfolio
-
Acadian Asset Management LLC Boston, MA3.72MShares$369 Million1.45% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.62MShares$359 Million0.11% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.59MShares$355 Million0.69% of portfolio
Latest Institutional Activity in CAH
Top Purchases
Top Sells
About CAH
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Insider Transactions at CAH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 15
2024
|
Michelle D. Greene Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
664
-3.3%
|
$72,376
$109.93 P/Share
|
Mar 15
2024
|
Robert Azelby Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,288
+50.0%
|
-
|
Feb 15
2024
|
Aaron E Alt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-6.55%
|
$197,657
$103.55 P/Share
|
Feb 15
2024
|
Michelle D. Greene Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
664
-3.19%
|
$68,392
$103.55 P/Share
|
Dec 01
2023
|
Mary C. Scherer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
217
-2.04%
|
$23,219
$107.08 P/Share
|
Dec 01
2023
|
Ola M Snow Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
382
-1.51%
|
$40,874
$107.08 P/Share
|
Dec 01
2023
|
Deborah Weitzman CEO, Pharmaceutical Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-1.81%
|
$68,266
$107.08 P/Share
|
Nov 27
2023
|
Deborah Weitzman CEO, Pharmaceutical Segment |
SELL
Open market or private sale
|
Direct |
36,642
-51.0%
|
$3,884,052
$106.31 P/Share
|
Nov 27
2023
|
Deborah Weitzman CEO, Pharmaceutical Segment |
BUY
Exercise of conversion of derivative security
|
Direct |
27,642
+12.76%
|
$2,128,434
$77.96 P/Share
|
Nov 15
2023
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+29.31%
|
-
|
Nov 15
2023
|
Michelle Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+27.09%
|
-
|
Nov 15
2023
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,185
-6.11%
|
$528,870
$102.9 P/Share
|
Nov 15
2023
|
Akhil Johri Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+8.92%
|
-
|
Nov 15
2023
|
Nancy Killefer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+7.33%
|
-
|
Nov 15
2023
|
Christine Mundkur Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+29.31%
|
-
|
Nov 15
2023
|
Sujatha Chandrasekaran Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+29.31%
|
-
|
Nov 15
2023
|
Patricia Hemingway Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+6.25%
|
-
|
Nov 15
2023
|
Sheri H. Edison Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+14.02%
|
-
|
Nov 15
2023
|
David C Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,965
+13.51%
|
-
|
Nov 15
2023
|
Gregory B Kenny Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,193
+5.08%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 299K shares |
---|---|
Exercise of conversion of derivative security | 52.6K shares |
Payment of exercise price or tax liability | 110K shares |
---|---|
Bona fide gift | 538 shares |
Open market or private sale | 171K shares |